Arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting

-- 100% orr at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached cr/scr -- -- 13 of 16 patients (81%) dosed more than 12 months ago reached cr/scr; 8 (50%) with emd; 9 (56%) remain in ongoing response with a median follow up of 17.7 months -- -- no cases of grade ≥3 crs and no delayed neurotoxicity or parkinsonian-like events observed at rp2d (n=25) -- -- phase 2 pivotal study on track to initiate by ye 2022 -- -- management to host live webcast event on sunday, june 5, 2022, at 7:00 p.m. cdt to discuss new positive cart-ddbcma data with a panel of clinician experts -- foster city, calif.
ACLX Ratings Summary
ACLX Quant Ranking